Lan Sun Wang, MD
Department of Gastroenterology Hepatology and Nutrition, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Clinical Associate Professor, Gastroenterology & Hepatology, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Section Director of Hepatology, Gastroenterology Hepat & Nutr, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Clinical Assistant Professor, Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2006 | Columbia University, College of Physicians and Surgeons, New York, New York, US, MD |
| 2002 | Rice University, Houston, Texas, US, BA in Computer Science |
Postgraduate Training
| 2009-2012 | Clinical Fellowship, Gastroenterology and Hepatology, Beth Israel Medical Center, New York, New York |
| 2007-2009 | Clinical Residency, Internal Medicine, Mount Sinai Hospital, New York, New York |
| 2006-2007 | Clinical Internship, Internal Medicine, Mount Sinai Hospital, New York, New York |
Licenses & Certifications
| 2015 | Texas State Medical Board |
| 2012 | American Board of Internal Medicine, Gastroenterology |
| 2009 | American Board of Internal Medicine, Internal Medicine |
Experience & Service
Faculty Academic Appointments
Clinical Assistant Professor, Gastroenterology Department, The University of Texas McGovern Medical School at Houston, Houston, TX, 2015 - 2018
Instructor, Gastroenterology, Hepatology, and Nutrition, Beth Israel Hospital Mount Sinai Health System, New York, NY, 2012 - 2015
Intramural Institutional Committee Activities
Chair, Problem Solving Committee of the Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Faculty Recognition Plan Committee of Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Faculty Recruitment Search Committee of Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Immuno-Oncology Toxicity Initiative, The University of Texas MD Anderson Cancer Center, 2020 - Present
Extramural Institutional Committee Activities
Member, Women in GI Committee, American College of Gastroenterology, 2022 - Present
Honors & Awards
| 2024 | Awesome Job Award, MD Anderson Cancer Center |
| 2023 | Awesome Job Award, MD Anderson Cancer Center |
| 2002 | Golden Key Society Member |
| 2002 | Phi Beta Kappa Honor Society |
| 2002 | Tau Beta Pi Engineering Honor Society |
| 1997 - 2001 | Rice University President's Honor Roll, Rice University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Journal Club: The evolving role of GLP1 agonists in MASLD. Panelist. Journal Club. Houston, Texas, US.
- 2025. Liver Disease - Basics and Grand Unification Theory. Invited. GI Fellowship Educational Series. Houston, Texas, US.
- 2022. NAFLD – A Multidisciplinary and Collaborative Approach. Invited. Houston, Texas, US.
- 2019. Hepatology in the setting of cancer: logistics and logic. Invited. Houston, Texas, US.
- 2019. Hepatitis B and Cancer. Invited. Houston, Texas, US.
National Presentations
- 2023. Immune Checkpoint Inhibitor Mediated Hepatobiliary Toxicity: The MD Anderson Experience. Invited. Jon Fryer MD CTC Lecture Series, US.
- 2022. Tocilizumab as an Effective Steroid-Sparing Agent for the Treatment of Recurrent and Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case Study and Insight into Pathophysiology. Poster. Annual Scientific Meeting of the American College of Gastroenterology (ACG). Charlotte, NC, US.
- 2021. Clinical Presentation, Treatment Strategies, and Chronic Sequelae of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: A Case Study. Poster. Annual Scientific Meeting of the American College of Gastroenterology (ACG). Las Vegas, NV, US.
- 2021. Severe Cholestasis as a Paraneoplastic Phenomenon Associated With Adrenocortical Carcinoma. Poster. Annual Scientific Meeting of the American College of Gastroenterology (ACG). Las Vegas, NV, US.
- 2021. Budesonide as an Alternative Steroid Agent, in Combination With Adjunctive Agents, for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study. Poster. Annual Scientific Meeting of the American College of Gastroenterology (ACG). Las Vegas, NV, US.
- 2021. Extrahepatic Biliary Sequelae in Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: Urgent Unmet Need for Early Effective Treatment. Conference. Annual Scientific Meeting of the American College of Gastroenterology (ACG). Las Vegas, NV, US.
- 2021. Tocilizumab as an alternative treatment strategy for immunotherapy-mediated hepatobiliary toxicity: addressing an urgent unmet need. Poster. Annual Scientific Meeting of the American College of Gastroenterology (ACG). Las Vegas, NV, US.
- 2021. Moderate Dose Steroid Treatment for Immune Checkpoint Inhibitor-Mediated Hepatotoxicity. Conference. Virtual, US.
- 2021. Diagnosis and Characteristics of Immune Checkpoint Inhibitor - Mediated Cholangiopathy: A Case Series. Conference. Diagnosis and Characteristics of Immune Checkpoint Inhibitor - Mediated Cholangiopathy: A Case Series, US.
Selected Publications
Peer-Reviewed Articles
- Torres, HA, Mustafayev, K, Juneau, RP, Hwang, JP, Wang, LS, Angelidakis, G, Hawk, E, Granwehr, BP, Yepez Guevara, E, Ying, AK. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center. JNCCN Journal of the National Comprehensive Cancer Network 22(2D), 2024. e-Pub 2024. PMID: 38729204.
- Shaikh, Abdullah S, Abraham, Susan C, Wang, Lan S, Torres, Harrys A, Zhang, Hao Chi. Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib. ACG Case Reports Journal 11(6):e01387, 2024. e-Pub 2024.
- Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol 118(9):1609-1617, 2023. PMID: 37307533.
- Nardo, M, Yilmaz, B, Nelson, BE, Torres, HA, Wang, LS, Granwehr, BP, Song, J, Dalla Pria, HR, Trinh, VA, Glitza, IC, Patel, SP, Tannir, NM, Kaseb, A, Altan, M, Lee, SS, Miller, E, Zhang, HC, Stephen, B, Naing, A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist 28(8):714-721, 2023. e-Pub 2023. PMID: 36952233.
- Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk 23(8):610-615, 2023. e-Pub 2023. PMID: 37150651.
- Chiu CY, Patel K, Thomas SK, Khawaja F, Dailey Garnes NJM, Lee HC, Ohanian M, Jiang Y, Wang LS, Hwang JP, Torres HA. Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodies. Hepatol Int 17(2):509-511, 2023. PMID: 36477692.
- Arango NP, Nishioka Y, Velasco J, Mahvash A, Mehran RJ, Wang LS, Taggart MW, Vauthey JN, Odisio BC. Involution of hepatocellular neoplasm after embolization of a portosystemic vascular shunt in an adult with Abernethy type II malformation. J Vasc Interv Radiol 32(9):1391-1393, 2021. PMID: 34462084.
- Pritchard H, Hwang JP, Angelidakis G, Yibirin M, Wang LS, Miller E, Torres HA. Hepatitis B virus reactivation in cancer patients receiving direct-acting antivirals for hepatitis C virus infection. J Viral Hepat 28(5):844-848, 2021. PMID: 33523503.
- Abu-Sbeih H, Chen E, Ahmed O, Mallepally N, Lum P, Qiao W, Lee HJ, Bresalier R, Wang LS, Weston B, Raju GS, Wang Y. Patients with Non-Hodgkin's Lymphoma Are at Risk of Adenomatous Colon Polyps. Dig Dis Sci 64(10):2965-2971, 2019. PMID: 31053975.
- Waintraub DJ, Serouya SM, Wang LS. An Incidental Finding of Esophageal Parakeratosis. Clin Gastroenterol Hepatol 14(2):A23, 2016. PMID: 26305072.
- Korman A, Kassab M, Wang LS, Patton B, Loree R, Reyes A, Carr-Locke D. Bronchoesophageal Fistula From Self Induced Vomiting. Am J Gastroenterol 106(2):s431, 2011.
- Murphy SJ, Wang LS, Anderson LA, Steinlauf A, Present DH. Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: A proposed method. Aliment Pharmacol Ther 30(10):1078-86, 2009. PMID: 19735230.
Review Articles
- Mouraa MJ, Chatterjeeb A, Walia S, Garzab DR, Salimc H, Rongd J, Menonb R, Jafrid F, Riverae AU, Mortand R, Palaskasf NL, Reynoldsg KL, Leafg RK, Kikanih N, Thomasa A, Zhanga HC, Wanga LS, Tummalai S, Al-Zubidij N, Sheshadrik A, Abudayyehl A, Jeffm YL, Wang Y. Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review. Expert Opinion on Drug Safety, 2026. e-Pub 2026.
- Wang LS, D'Souza LS, Jacobson IM. Hepatitis C. J Med Virol 88(11):1844-1855, 2016. PMID: 27097298.
Abstracts
- Machado A, Caskey K, Shaikh A, Wang L, Miller E, Wang Y, Zhang H. Oral Budesonide for the Treatment of Immune Checkpoint Inhibitor-Mediated Hepatobiliary Toxicities: A Case Series. Digestive Diseases Week, 2025.
- Torres HA, Mustafayev K, Juneau R, Hwang JP, Wang LS, Angelidakis G, Granwehr BP, Yepez Guevara E, Ying AK. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2023.
- Zhang HC, Miller E, Zurita A, Wang L. Early Tocilizumab as a Rescue Therapy for Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity. Annual Scientific Meeting of the American College of Gastroenterology (ACG), 2023.
- Zhang HC, Miller E, Msaouel P, Wang L. Implementation of an Enhanced "Step-Up" Approach Towards Early Tocilizumab for Management of Immune Checkpoint Inhibitor-Mediated Hepatotoxicity. Annual Scientific Meeting of the American College of Gastroenterology (ACG), 2023.
- Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors. 4th Symposium on Infectious Diseases in the Immunocompromised Host, 2023.
- Chiu CY, Patel K, Thomas SK, Khawaja F, Dailey Garnes NJM, Lee HC, Ohanian M, Jiang Y, Wang LS, Hwang JP, Torres HA. Hepatitis B virus reactivation in patients receiving anti-CD38 monoclonal antibodies. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2022.
- Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2022.
- Chopra M, Waters R, Wang L, Zhang HC. Metastatic Merkel Cell Carcinoma Presenting as Silent Infiltrative Liver Disease. Annual Scientific Meeting of the American College of Gastroenterology (ACG), 2022.
- Zhang HC, Miller E, Wang L. Early Use of Tocilizumab as an Effective Steroid-Sparing Strategy for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiopathy. Annual Scientific Meeting of the American College of Gastroenterology (ACG), 2022.
- Muftah AA, Waters R, Wang L, Zhang HC. Vanishing Bile Duct Syndrome in the Setting of Newly Diagnosed Hodgkin Lymphoma. Annual Scientific Meeting of the American College of Gastroenterology (ACG), 2022.
- Zhang HC, Eyada M, Wang LS. Tocilizumab as an alternative treatment strategy for imunotherapy-mediated hepatobiliary toxicity: addressing an urgent unmet need. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2021. e-Pub 2021.
- Zhang HC, Wang LS, Miller E. Diagnosis and Characteristics of Immune Checkpoint Inhibitor - Mediated Cholangiopathy: A Case Series. Digestive Diseases Week, 2021. e-Pub 2021.
- Wang LS, Zhang HC, Miller E. Moderate Dose Steroid Treatment for Immune Checkpoint Inhibitor-Mediated Hepatotoxicity. Digestive Diseases Week 160(6):S-790, 2021. e-Pub 2021.
- Yibirin M, Pundhir P, Yepez-Guevara E, Granwehr BP, Kaseb A, Patel S, Naing A, Shah AY, Skoulidis F, Tawbi HA, Zhang HC, Wang LS, Miller E, Torres HA. Safety of Immune Checkpoint Inhibitors in Cancer Patients with Chronic Hepatitis C Infection: A Prospective Observational Study. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2020.
- De la Cruz RD, Wang LS, Wong C, Ng A, Eng R, Eng LM, Theise N. Concomitant Non-Alcoholic Fatty Liver Disease Drives Progression of Overall Liver Disease More Than Chronic Hepatitis B alone in Chinese-Americans. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2015.
- Bichoupan K, Waintraub DJ, Patel NM, Chekuri S, Hartman J, Harty A, Motamed DB, Stivala A, Khaitova V, Woody A, Bansal M, Grewal P, Agarwal R, Chang CY, Leong J, Im GY, Liu L, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Min A, Wang LS, Branch AD. Clinical Performance of Sofosbuvir and Ledipasvir for HCV Genotype 1 in New York City. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2015.
- Tsyman D, Wang L, Zhang L, Yiu P, Ng A. Think Twice With That Tuna Tartare. Annual Scientific Meeting of the American College of Gastroenterology (ACG), 2015.
- Rubinov J, Broder A, Wang LS, Yuan A, Melstrom K. Intraperitoneal Mucinous Adenocarcinoma. Annual Scientific Meeting of the American College of Gastroenterology (ACG), 2014.
- Ji Y, Wang LS, Shi H, Luo R, Wong C, Bodenheimer H, Theise ND. A Comparison of Histopathology of Liver Biopsy of Chronic Hepatitis B Patients between Chinese-Americans in New York and Chinese in Shanghai. Digestive Diseases Week, 2014.
- Kutner M, Wang LS, Rubinov J, Korman A. An Unusual Cause of Ascites. Annual Scientific Meeting of the American College of Gastroenterology, 2013.
- Singh S, Wong C, Wang LS, MacGowen D, Fischer H, Theise N, Bodenheimer H. Myositis Portends Primary Biliary Cirrhosis: A Case Series. Annual Scientific Meeting of the American College of Gastroenterology, 2013.
- Singh S, Wang LS, Brown W. Nonsurgical Management of a Fish Jaw Causing Esophageal Perforation. Annual Scientific Meeting of the American College of Gastroenterology, 2013.
- Amorus L, Kaga M, Abelow C, Korman A, Wang LS. Gastric Ulcer Causing Recurrent Hiccups: A Case Report. Annual Scientific Meeting of the American College of Gastroenterology, 2013.
- Wang LS. Acute Pelvis After Colonoscopy. Annual Scientific Meeting of the American College of Gastroenterology, 2013.
- Nichols G, Wang LS, Pesce P. Monoclonal Immunoglobulin M Proteins - A Clinical Database. Blood 102(11):373b, 2003. e-Pub 2003.
Book Chapters
- Zhang HC, Ngo S, Chatterjee D, Miller E, Zurita AJ, Wang L. Hepatobiliary Toxicity Secondary to Immune Checkpoint Inhibitor Therapy: Early Tocilizumab Treatment to Decouple Steroid Dependency. In: Challenging Cases in Immunotherapy Related Organ Toxicities. 1. Springer Cham, 243-256, 2025.
- Zhang HC, Rivera AU, Miller E, Chun YS, Ledet CR, Wang L. Cholangiohepatitis with Extrahepatic Cholangiopathy and Cholecystitis Secondary to Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities. 1. Springer Cham, 257-265, 2025.
- Zhang HC, Shah J, Rashid A, Miller E, Msaouel P, Wang L. Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: Personalized Management Based on Evolving Biochemical Behaviors. In: Challenging Cases in Immunotherapy Related Organ Toxicities. 1. Springer Cham, 2025.
- Zhang, HC, Wang, LS, Miller, E. Hepatology (Liver and Bile Duct). In: Managing Immunotherapy Related Organ Toxicities. Springer, Cham, 119-165, 2022.
- Zhang, HC, Wang, LS, Miller, E. Hepatobiliary and Pancreatic Adverse Events. In: Immunotherapy. Springer, Cham, 339-355, 2021.
Patient Reviews
CV information above last modified July 22, 2026